Matching articles for "dexamethasone"
Issue 1725 · March 31, 2025 Free
Treatment of Allergic Rhinitis and Allergic Conjunctivitis

Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2025 Mar 31; 67(1725):49-56 doi:10.58347/tml.2025.1725a
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1717 · December 9, 2024
Isatuximab (Sarclisa) for Multiple Myeloma (online only)

Isatuximab-irfc ( Sarclisa – Sanofi), a CD38-directed cytolytic antibody, has been approved by the FDA for treatment of newly diagnosed multiple myeloma in adults who are not eligible for autologous stem…

Med Lett Drugs Ther. 2024 Dec 9; 66(1717):e200-1 doi:10.58347/tml.2024.1717e
Isatuximab-irfc ( Sarclisa – Sanofi), a CD38-directed cytolytic antibody, has been approved by the FDA for treatment of newly diagnosed multiple myeloma in adults who are not eligible for autologous stem cell transplantation (ASCT). The drug was approved earlier for treatment of relapsed or treatment-refractory multiple myeloma.
Issue 1677 · May 29, 2023 Free
COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19

The investigational anti-complement component 5a (C5a) antibody vilobelimab ( Gohibic – InflaRx) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of hospitalized adults with…

Med Lett Drugs Ther. 2023 May 29; 65(1677):86-7 doi:10.58347/tml.2023.1677d
The investigational anti-complement component 5a (C5a) antibody vilobelimab ( Gohibic – InflaRx) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of hospitalized adults with COVID-19 beginning within 48 hours after invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) is started. Vilobelimab is the first anti-C5a antibody to become available in the US.
Issue 1672 · March 20, 2023
A Dexamethasone Ophthalmic Insert (Dextenza) for Allergic Conjunctivitis

The FDA has approved Dextenza (Ocular Therapeutix), a dexamethasone ophthalmic insert, for treatment of ocular itching associated with allergic conjunctivitis. Dextenza was approved earlier for treatment of…

Med Lett Drugs Ther. 2023 Mar 20; 65(1672):45-6 doi:10.58347/tml.2023.1672b
The FDA has approved Dextenza (Ocular Therapeutix), a dexamethasone ophthalmic insert, for treatment of ocular itching associated with allergic conjunctivitis. Dextenza was approved earlier for treatment of ocular inflammation and pain following ophthalmic surgery.
Issue 1667 · January 9, 2023 Free
COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only)

The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has been approved by the FDA for IV treatment of COVID-19 in hospitalized adults who are receiving a systemic corticosteroid…

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):e9 doi:10.58347/tml.2023.1667d
The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has been approved by the FDA for IV treatment of COVID-19 in hospitalized adults who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab was previously available for this indication under an Emergency Use Authorization (EUA); it remains available under an EUA for treatment of children 2-17 years old who are hospitalized with COVID-19 and require oxygen support.
Issue 1665 · December 12, 2022 Free
An EUA for Anakinra (Kineret) for COVID-19 (online only)

The recombinant interleukin-1 (IL-1) receptor antagonist anakinra ( Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19…

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e203-4
The recombinant interleukin-1 (IL-1) receptor antagonist anakinra ( Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19 pneumonia who require low- or high-flow supplemental oxygen, are at risk of progressing to severe respiratory failure, and are likely to have elevated plasma levels of soluble urokinase plasminogen activator receptor (suPAR). Anakinra has been available in the US for years; it is FDA-approved for multiple indications, including rheumatoid arthritis. Assays for suPAR are not commercially available in the US.
Issue 1629 · July 26, 2021 Free
An EUA for Tocilizumab (Actemra) for COVID-19

The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has received an Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2 years…

Med Lett Drugs Ther. 2021 Jul 26; 63(1629):113-4
The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has received an Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2 years old who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab has been approved by the FDA for various indications, including rheumatoid arthritis and juvenile idiopathic arthritis.
Issue 1614 · December 28, 2020
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting

The FDA has approved IV amisulpride ( Barhemsys – Acacia), a selective dopamine-2 and -3 (D 2 /D 3 ) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults.…

Med Lett Drugs Ther. 2020 Dec 28; 62(1614):205-8
The FDA has approved IV amisulpride ( Barhemsys – Acacia), a selective dopamine-2 and -3 (D 2 /D 3 ) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults. It is the first antiemetic to be approved for rescue treatment of PONV in patients who have symptoms despite receiving antiemetic prophylaxis. Oral formulations of amisulpride are available in Europe for treatment of schizophrenia and acute psychotic episodes.
Issue 1582 · October 7, 2019
Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness (online only)

View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):e161-3
View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness
Issue 1561 · December 3, 2018
IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)

The FDA has approved Cinvanti (Heron), an IV emulsion formulation of the substance P/neurokinin-1 (NK1) receptor antagonist aprepitant, for prevention of acute and delayed chemotherapy-induced nausea and…

Med Lett Drugs Ther. 2018 Dec 3; 60(1561):e200-1
The FDA has approved Cinvanti (Heron), an IV emulsion formulation of the substance P/neurokinin-1 (NK1) receptor antagonist aprepitant, for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Aprepitant is also available in oral capsule and suspension formulations ( Emend , and generics), and fosaprepitant, a prodrug of aprepitant, is available in an IV formulation ( Emend for injection).
Issue 1553 · August 13, 2018
Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa

The FDA has approved a 6% otic suspension formulation of the fluoroquinolone antibiotic ciprofloxacin ( Otiprio – Otonomy) for single-dose treatment of acute otitis externa (swimmer's ear) caused by…

Med Lett Drugs Ther. 2018 Aug 13; 60(1553):135-6
The FDA has approved a 6% otic suspension formulation of the fluoroquinolone antibiotic ciprofloxacin ( Otiprio – Otonomy) for single-dose treatment of acute otitis externa (swimmer's ear) caused by Pseudomonas aeruginosa or Staphylococcus aureus in patients ≥6 months old. Otiprio was approved earlier for prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement.
Issue 1495 · May 23, 2016
Ciprofloxacin (Otiprio) for Tympanostomy Tube Insertion

The FDA has approved ciprofloxacin 6% otic suspension ( Otiprio – Otonomy) for single-dose prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement. It…

Med Lett Drugs Ther. 2016 May 23; 58(1495):69-70
The FDA has approved ciprofloxacin 6% otic suspension ( Otiprio – Otonomy) for single-dose prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement. It is the first drug to be approved for this indication in the US. Otic formulations of the fluoroquinolone antibiotics ofloxacin ( Floxin Otic , and generics) and ciprofloxacin (plus dexamethasone; Ciprodex ) have been available for years for treatment of acute otitis media in children with tympanostomy tubes; an otic suspension containing ciprofloxacin and fluocinolone acetonide (Otovel) has recently been approved for the same indication and will be reviewed in a future issue.
Issue 1495 · May 23, 2016
Three New Drugs for Multiple Myeloma (online only)

The FDA recently approved ixazomib ( Ninlaro – Takeda), daratumumab ( Darzalex – Janssen Biotech), and elotuzumab ( Empliciti – BMS) for treatment of relapsed and/or refractory multiple myeloma.

Med Lett Drugs Ther. 2016 May 23; 58(1495):e70-1
The FDA recently approved ixazomib ( Ninlaro – Takeda), daratumumab ( Darzalex – Janssen Biotech), and elotuzumab ( Empliciti – BMS) for treatment of relapsed and/or refractory multiple myeloma.
Issue 1487 · February 1, 2016
Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting

The FDA has approved rolapitant ( Varubi – Tesaro), an oral substance P/neurokinin 1 (NK 1 ) receptor antagonist, for use with other antiemetics to prevent delayed nausea and vomiting associated with cancer…

Med Lett Drugs Ther. 2016 Feb 1; 58(1487):17-8
The FDA has approved rolapitant ( Varubi – Tesaro), an oral substance P/neurokinin 1 (NK 1 ) receptor antagonist, for use with other antiemetics to prevent delayed nausea and vomiting associated with cancer chemotherapy in adults. It is the third substance P/NK 1 receptor antagonist to be approved in the US; aprepitant (Emend) and netupitant (only available in combination with the 5-HT 3 receptor antagonist palonosetron as Akynzeo) were approved earlier for prevention of both acute and delayed chemotherapy-induced nausea and vomiting.
Issue 1475 · August 17, 2015
Panobinostat (Farydak) for Multiple Myeloma (online only)

The FDA has approved panobinostat ( Farydak – Novartis), an oral histone deacetylase (HDAC) inhibitor, for use in combination with bortezomib (Velcade) and dexamethasone for treatment of patients with…

Med Lett Drugs Ther. 2015 Aug 17; 57(1475):e118-9
The FDA has approved panobinostat ( Farydak – Novartis), an oral histone deacetylase (HDAC) inhibitor, for use in combination with bortezomib (Velcade) and dexamethasone for treatment of patients with multiple myeloma who have received at least 2 prior therapies including bortezomib and an immunomodulatory drug. It is the first HDAC inhibitor to be approved for this indication.
Issue 1467 · April 27, 2015
Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting

The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK 1 ) receptor antagonist netupitant and the serotonin-3 (5-HT 3 ) receptor antagonist…

Med Lett Drugs Ther. 2015 Apr 27; 57(1467):61-3
The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK 1 ) receptor antagonist netupitant and the serotonin-3 (5-HT 3 ) receptor antagonist palonosetron, for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy in adults. Akynzeo is the first product to combine drugs from these two classes. Palonosetron (Aloxi) is also available as a single agent for prevention of chemotherapy-induced and postoperative nausea and vomiting. Netupitant is the second substance P/NK 1 receptor antagonist to be approved in the US; aprepitant (Emend) was the first.
Issue 1466 · April 13, 2015
Advice for Travelers

Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their…

Med Lett Drugs Ther. 2015 Apr 13; 57(1466):52-8
Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their destination, length of stay, and planned activities were reviewed in a previous issue.
Issue 118 · June 1, 2012
Advice for Travelers

Patients planning to travel to other countries often ask for information about appropriate vaccines and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for…

Treat Guidel Med Lett. 2012 Jun; 10(118):45-56
Patients planning to travel to other countries often ask for information about appropriate vaccines and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel. Guidelines are also available from the Infectious Diseases Society of America (IDSA).
Issue 94 · June 1, 2010
Drugs for Bacterial Infections

The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter…

Treat Guidel Med Lett. 2010 Jun; 8(94):43-52
The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 88 · December 1, 2009
Antifungal Drugs

The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online…

Treat Guidel Med Lett. 2009 Dec; 7(88):95-102
The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from the Infectious Diseases Society of America ( www.idsociety.org ).
Issue 87 · November 1, 2009
Advice for Travelers

Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases…

Treat Guidel Med Lett. 2009 Nov; 7(87):83-94
Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases Society of America (IDSA).
Issue 84 · August 1, 2009
Drugs for Thyroid Disorders

Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.

Treat Guidel Med Lett. 2009 Aug; 7(84):57-64
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Issue 1301 · December 15, 2008
A Granisetron Patch (Sancuso)

The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):103-0
The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin receptor antagonists are available in the US in intravenous (IV) formulations for prevention of nausea and vomiting due to cancer chemotherapy, and 3 of these are also available for oral use. Now the FDA has approved one of these, granisetron, in a transdermal formulation ( Sancuso - ProStrakan).
Issue 65 · January 1, 2008
Antifungal Drugs

The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from…

Treat Guidel Med Lett. 2008 Jan; 6(65):1-8
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from the Infectious Diseases Society of America ( www.idsociety.org ).
Issue 57 · May 1, 2007
Choice of Antibacterial Drugs

Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric…

Treat Guidel Med Lett. 2007 May; 5(57):33-50
Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric treatment for some common types of infections are summarized in the text and a table listing the drugs of choice and alternatives for each pathogen begins on page 40. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 45 · May 1, 2006
Advice for Travelers

Patients planning to travel to other countries often ask physicians for information about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers…

Treat Guidel Med Lett. 2006 May; 4(45):25-34
Patients planning to travel to other countries often ask physicians for information about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control and Prevention at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel .
Issue 21 · May 1, 2004
Advice for Travelers

Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for…

Treat Guidel Med Lett. 2004 May; 2(21):33-40
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control (CDC) at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel . Recommendations for the treatment of parasitic diseases are available in the public reading room of The Medical Letter's web site.
Issue 1180 · April 12, 2004
Pemetrexed (Alimta) for Mesothelioma

The combination of pemetrexed ( Alimta - Lilly) and cisplatin is the first chemotherapy regimen approved by the FDA for treatment of malignant pleural mesothelioma. This uncommon malignancy, which has been…

Med Lett Drugs Ther. 2004 Apr 12; 46(1180):31-2
The combination of pemetrexed ( Alimta - Lilly) and cisplatin is the first chemotherapy regimen approved by the FDA for treatment of malignant pleural mesothelioma. This uncommon malignancy, which has been linked to asbestos exposure, was previously considered unresponsive to chemotherapy, with a median survival of 6-8 months from diagnosis (VW Rusch, J Clin Oncol 2003; 21:2629).
Issue 19 · March 1, 2004
Choice of Antibacterial Drugs

New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the…

Treat Guidel Med Lett. 2004 Mar; 2(19):13-22
New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the drugs of choice and alternatives for each pathogen begins on page 18. These recommendations are based on results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants. Local resistance patterns should be taken into account. Trade names are listed on page 24.
Issue 1162 · August 4, 2003
Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 )…

Med Lett Drugs Ther. 2003 Aug 4; 45(1162):62-3
Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 ) receptor antagonists to prevent nausea and vomiting caused by highly emetogenic anticancer drugs such as cisplatin.
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 1141 · October 14, 2002
Generic drugs

When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the…

Med Lett Drugs Ther. 2002 Oct 14; 44(1141):89-90
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the brand-name product?
Issue 1128 · April 15, 2002
Advice for Travelers

Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the CDC at…

Med Lett Drugs Ther. 2002 Apr 15; 44(1128):33-8
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the CDC at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel .
Issue 1026 · May 8, 1998
Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Dolasetron ( Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT 3 ) receptor antagonist similar to ondansetron (Zofran) and granisetron ( Kytril - Medical Letter, 36:61, 1994) is now available for…

Med Lett Drugs Ther. 1998 May 8; 40(1026):53-4
Dolasetron ( Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT 3 ) receptor antagonist similar to ondansetron (Zofran) and granisetron ( Kytril - Medical Letter, 36:61, 1994) is now available for both oral and intravenous use in prevention of nausea and vomiting due to cancer chemotherapy. A 5-HT 3 antagonist plus dexamethasone ( Decadron , and others) is the most effective regimen for prevention of acute vomiting caused by cancer chemotherapy. Dolasetron has also been approved by the FDA for prevention and treatment of postoperative nausea and vomiting.
Issue 926 · July 8, 1994
Granisetron to Prevent Vomiting After Cancer Chemotherapy

Granisetron, a serotonin (5-HT) antagonist similar to ondansetron, was recently approved by the US Food and Drug Administration for prevention of nausea and vomiting due to cancer chemotherapy. Although…

Med Lett Drugs Ther. 1994 Jul 8; 36(926):61-2
Granisetron, a serotonin (5-HT) antagonist similar to ondansetron, was recently approved by the US Food and Drug Administration for prevention of nausea and vomiting due to cancer chemotherapy. Although available in an oral formulation in other countries, granisetron is available here only for intravenous (IV) use.
Issue 912 · December 24, 1993
Drugs for Vomiting Caused by Cancer Chemotherapy

Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.

Med Lett Drugs Ther. 1993 Dec 24; 35(912):124-6
Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.
Issue 896 · May 14, 1993
Paclitaxel (Taxol) for Ovarian Cancer

Paclitaxel ( Taxol - Bristol-Myers Squibb) is now available in the USA for treatment of metastatic ovarian cancer refractory to other drugs. The new drug is a natural product extracted in small amounts from…

Med Lett Drugs Ther. 1993 May 14; 35(896):39-40
Paclitaxel ( Taxol - Bristol-Myers Squibb) is now available in the USA for treatment of metastatic ovarian cancer refractory to other drugs. The new drug is a natural product extracted in small amounts from the inner bark of the Western yew tree found mainly in the Pacific northwest ( Taxus brevifolia ). Efforts to synthesize the drug have been unsuccessful to date, but a semi-synthetic product (taxotere) prepared from the needles of European yews has shown some promise (R Pazdur et al, J Natl Cancer Inst, 89:1781, 1992), and a fungus ( Taxomyces andreanae ) growing on the Pacific yew was recently found to produce paclitaxel even after removal from the tree (A Stierle et al, Science, 260:214, April 9, 1993). In any case, supply of the drug is currently keeping up with demand.
Issue 878 · September 4, 1992
High Altitude Sickness

Rapid exposure to altitudes more than 8,000 feet above sea level can cause serious medical problems. Since the last Medical Letter article on this subject (Vol. 30, page 89, 1988), some new information on…

Med Lett Drugs Ther. 1992 Sep 4; 34(878):84-6
Rapid exposure to altitudes more than 8,000 feet above sea level can cause serious medical problems. Since the last Medical Letter article on this subject (Vol. 30, page 89, 1988), some new information on prevention and treatment of these disorders has been reported.
Issue 859 · December 13, 1991
Intranasal Triamcinolone For Allergic Rhinitis

An intranasal formulation of the corticosteroid triamcinolone ( Nasacort - Rh ne- Poulenc Rorer) was recently approved by the US Food and Drug Administration for once-daily treatment of seasonal and perennial…

Med Lett Drugs Ther. 1991 Dec 13; 33(859):116-7
An intranasal formulation of the corticosteroid triamcinolone ( Nasacort - Rh ne- Poulenc Rorer) was recently approved by the US Food and Drug Administration for once-daily treatment of seasonal and perennial allergic rhinitis.
Issue 857 · November 15, 1991
Topical Corticosteroids

Two new topical corticosteroids - fluticasone ( Cutivate - Glaxo), a mediumpotency product, and halobetasol propionate ( Ultravate - Westwood-Squibb), a superhigh- potency drug- were recently approved for…

Med Lett Drugs Ther. 1991 Nov 15; 33(857):108-10
Two new topical corticosteroids - fluticasone ( Cutivate - Glaxo), a mediumpotency product, and halobetasol propionate ( Ultravate - Westwood-Squibb), a superhigh- potency drug- were recently approved for marketing by the US Food and Drug Administration.
Issue 847 · June 28, 1991
Ondansentron To Prevent Vomiting After Cancer Chemotherapy

Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An…

Med Lett Drugs Ther. 1991 Jun 28; 33(847):63-4
Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An oral formulation is available in many other countries.
Issue 775 · September 23, 1988
High Altitude Sickness

Rapid exposure to altitudes more than 8,000 feet above sea level can cause serious medical problems. Some new approaches to prevention and treatment of these disorders have recently been reported.

Med Lett Drugs Ther. 1988 Sep 23; 30(775):89-91
Rapid exposure to altitudes more than 8,000 feet above sea level can cause serious medical problems. Some new approaches to prevention and treatment of these disorders have recently been reported.
Issue 756 · January 1, 1988
Nabilone And Other Antiemetic For Cancer Patients

Nabilone ( Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and…

Med Lett Drugs Ther. 1988 Jan 1; 30(756):2-4
Nabilone ( Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and vomiting associated with cancer chemotherapy. Oral THC itself, known generically as dronabinol ( Marinol ), is also commercially available as an antiemetic for cancer patients (Medical Letter, 27:97, 1985). Other drugs used for this purpose include metoclopramide ( Reglan - Medical Letter, 24:67, 1982), prochlorperazine ( Compazine ; and others), haloperidol ( Haldol ; and others), and corticosteroids. Benzodiazepines, such as lorazepam ( Ativan ; and others), are used to treat anticipatory nausea and vomiting that occurs before chemotherapy begins.